Abstract
Aging is a well established risk factor for Parkinson's disease (PD). In the present studies, we determined age‐related effects of 1‐methyl‐4‐phenyl‐1,2.3,6‐tetraphydropyridine (MPTP) treatment on DA, norepinephrine (NE) and serotonin (5‐HT) in the striatum and prefrontal cortex (PFC). Male C57BL/6J mice were subjected to i.p. administration of (1) chronic MPTP treatment (20 mg/kg MPTP for 5 days) at 9 weeks of age or at 18 months of age and sacrificed at 3 weeks after MPTP treatment, and (2) acute MPTP treatment (4 doses of 20 mg/kg at 2 hrs interval) at 9 weeks of age and were sacrificed either at 12 weeks of age or at 18 months of age. Saline was used as vehicle control. Monoamines concentrations in the striatum and PFC were analysed by HPLC. Chronic MPTP treatment decreased striatal DA concentration by 25% in the 9‐ week old mice and 67% in the 18‐month old mice; decreased significantly striatal NE concentrations in the 18‐month old mice. However, striatal 5‐HT and monoamines concentrations at PFC were not altered following chronic MPTP treatment. After acute MPTP treatment, the striatal DA concentrations were significantly decreased at both survival periods and significant decreases in 5‐HT and NE concentrations in the PFC at both survival periods. The data suggest that aging may increase the vulnerability of the dopaminergic, adrenergic and serotonergic systems to MPTP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
